Residual thrombosis after a first episode of proximal deep venous thrombosis

Blood Coagul Fibrinolysis. 2013 Jun;24(4):335-60. doi: 10.1097/MBC.0b013e32835c32ef.

Abstract

The aim of this study was to analyse the normalization rate of compression ultrasonography after a first episode of proximal deep venous thrombosis (DVT). Patients underwent compressive ultrasound (C-US) examinations during the 3-6 months following the first proximal DVT episode. Normalization rate of compressive ultrasound (C-US) during the follow-up period was 26.4% [95% confidence interval, 16.3-37.3]. Allelic variation in factor XIII gene (Val34Leu) significantly affected the improvement of popliteal residual thrombi (P = 0.019). We also observed a significant negative correlation between D-dimer levels at 3 months and improvement of popliteal residual thrombi (P = 0.016). There was a significant positive correlation between baseline lumen diameter of the femoral thrombi and IL-8 cytokine (P = 0.015). A significant difference was also found between 1 month-tumor necrosis factor (TNF)-α levels and improvement of residual thrombi (P = 0.047). Our results show that normalization after a standard period of anticoagulation is not frequent and procoagulant and inflammatory biomarkers and also some genetic variations might be related to the resolution of thrombosis.

MeSH terms

  • Adult
  • Aged
  • Alleles
  • Anticoagulants / therapeutic use
  • Biomarkers / blood
  • Factor XIII / genetics*
  • Factor XIII / metabolism
  • Female
  • Fibrin Fibrinogen Degradation Products / metabolism
  • Humans
  • Interleukin-8 / blood
  • Male
  • Middle Aged
  • Mutation
  • Polymorphism, Genetic
  • Popliteal Vein / diagnostic imaging
  • Popliteal Vein / drug effects
  • Popliteal Vein / pathology*
  • Risk Factors
  • Tumor Necrosis Factor-alpha / blood
  • Ultrasonography
  • Venous Thrombosis / diagnostic imaging
  • Venous Thrombosis / drug therapy
  • Venous Thrombosis / genetics
  • Venous Thrombosis / pathology*

Substances

  • Anticoagulants
  • Biomarkers
  • Fibrin Fibrinogen Degradation Products
  • Interleukin-8
  • Tumor Necrosis Factor-alpha
  • fibrin fragment D
  • Factor XIII